Scancell Holdings, a group focused on the development of novel immunotherapies, has appointed Dr Cliff Holloway as its chief executive officer effective 10 January 2018.
Holloway’s new role will see him drive progress of Scancell’s immunotherapy platforms including ImmunoBody and Moditope, and oversee their commercialisation.
He said: “Having cemented a business relationship with Scancell in 2006 I have followed the company’s significant progress with great interest.
“I am delighted to be joining the Scancell team at this exciting time in the company’s evolution and look forward to building on the many achievements to date, and to progressing these important new cancer therapies for patients.”
With over 25 years’ experience in the life sciences industry, Holloway most joins from Benitec Biopharma, where he held the role of chief business and operating officer.
Prior to this, he was chief executive officer and managing director of Sienna Cancer Diagnostics, and has held roles for Immune System Therapeutics and Biosceptre International.
John Chiplin, executive chairman, Scancell, said: “Cliff’s extensive experience and accomplishments speaks volumes and his expertise in cancer therapeutics will be invaluable as we drive our immunotherapy vaccines through the clinic, with the aim to provide new treatment options for patients with debilitating cancers.”
Holloway succeeds Richard Goodfellow, who will remain on the company’s board of directors.